Illumina Inc (Illumina) is a medical device company that focuses on DNA sequencing and array-based life sciences technologies. Its products are used in various applications, including oncology, genetic disease, infectious disease, multiomics, drug discovery, microbial genomics, reproductive health, molecular and cell biology, agriculture, and conservation. It also offers BaseSpace Informatics Suite to manage customers' biological samples and sequencing runs, process and analyze the raw genomic data, and derive meaningful results; DRAGEN Bio-IT Platform is used for secondary analysis and analyzes sequencing data from a variety of experiment types, including whole genomes, whole exomes, germline and somatic datasets, and RNA sequencing experiments; and Connected analytics, an integrated bioinformatics solution that provides a comprehensive, private, cloud-based data platform.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Illumina’s research and development (R&D) initiatives focus on enabling researchers and clinicians to make impactful genomic discoveries through innovative technology and product development. The company prioritizes internal research and development to create advanced products, driving the multiomics revolution with next-generation sequencing (NGS) and multiomics technologies. Its key innovations include constellation-mapped reads, spatial transcriptomics, and a 5-base solution for methylation studies, all aimed at enhancing genomic insights and accelerating discovery. The R&D unit of Illumina is responsible for prioritizing internal R&D, continually competing against itself to create better products. The unit focuses on developing technologies that empower researchers to perform studies at the required throughput, scale, and price, with an emphasis on ease-of-use and sustainability. In FY2025, the company spent US$967 million on its R&D activities, which as a percentage of revenue stood at 22.3%. As of December 2025, the company operated labs in the US, the UK, China, and India, among others. As of December 2025, the company owned or had exclusive licenses to 1,380 issued US patents and 1,120 pending US patent applications, along with 7,653 issued patents outside the US and 4,218 pending patent applications outside the US.